1. Generics Bulletin
  2. >>Products

Glenmark Celebrates European Ryaltris Approvals

Has Marketing Authorizations In 13 European Countries; Menarini Set To Launch

 
• By Dave Wallace

Glenmark is celebrating the approval of its Ryaltris nasal spray in 13 European countries, with the Indian company and partner Menarini set to begin rolling out the allergic rhinitis combination product.

Glenmark Website Screen
Glenmark has received 13 European approvals for Ryaltris • Source: Alamy

Glenmark has announced the approval in 13 European countries of its Ryaltris (olopatadine hydrochloride / mometasone furoate) 665mcg/25mcg nasal spray. The Indian company and marketing partner Menarini are set to begin rolling out the treatment for seasonal and perennial allergic rhinitis in adults and children over 12, following earlier launches in certain other international territories.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Value Added Medicines

More from Products

Sandoz And Henlius Join Forces With $300m Ipilimumab Deal

 
• By Dave Wallace

Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.

Discounted Ustekinumab Biosimilars Further Dent J&J’s Q1 Stelara Sales

 
• By Urtė Fultinavičiūtė

With discounts reaching up to 90%, ustekinumab biosimilars have eroded originator Stelara’s sales as expected. In its latest quarterly biosimilar market report, Samsung Bioepis also analyzed the latest regulatory steps to streamline biosimilar development.

Iconovo Slims Down As It Focuses On Commercialization

 
• By Dave Wallace

As its need for development resources declines, Iconovo is cutting staff to save money as it moves to the commercialization stage for its portfolio of off-patent inhaled products.